Sareum Plc logo

Sareum Plc(LSE) SAR

Market Cap£38.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-82%
5 Year-92%
1 Year+90%
1 Month-14%
£0.27
-1.27%
-0.00Today
Sareum Plc last closing stock price
MetricPriceDate
Last closeGBX 27.502026-10-13
Sareum Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 27.502026-10-06
1 month-14.06%GBX 32.002026-09-11
3 month+17.02%GBX 23.502026-07-15
Year to date+83.33%GBX 15.002025-12-31
1 year+89.66%GBX 14.502025-10-13
3 year-65.63%GBX 80.002023-10-13
5 year-91.54%GBX 325.002021-10-14
Since inception-81.67%GBX 1.502004-10-11

Sareum Plc Financials at a Glance

Market Cap

£38.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£7.00M

EPS (TTM)

-£0.04

P/E Ratio

-7.49

Dividend

£0.00

Beta (Volatility)

-0.00 (Low)

Price

£0.27

Volume

126,368

Open

£0.28

Previous Close

£0.27

Daily Range

£0.27 - £0.28

52-Week Range

£0.12 - £0.40

Estimated Earnings Date

Oct 26, 2026

SAR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sareum Plc

Sareum Holdings plc is a specialized pharmaceutical company focused on discovering and advancing innovative therapeutic compounds for cancer and autoimmune conditions. The company utilizes its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform, with a portfolio that includes programs targeting key kinases.

Products and Services
  • Development of small-molecule drugs for cancer and autoimmune diseases
  • Proprietary Sareum Kinase Inhibitor Library for drug discovery
  • Strategic partnerships with leading biomedical institutions
Growth Outlook
  • Strong pipeline with multiple drug candidates in development
  • Recent partnerships enhance research capabilities and market reach
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Recent quarterly net income of -£1.65 million, reflecting ongoing investment in R&D
  • Cash and cash equivalents of £2.49 million as of the latest quarter
  • Trailing twelve months (TTM) P/E ratio of -8.24 indicates potential for future profitability
Sareum Holdings plc operates in the biotechnology sector, primarily targeting unmet medical needs in oncology and autoimmune diseases. The company has established a solid foundation through its innovative drug discovery platform and strategic collaborations, which are crucial for advancing its therapeutic candidates. Despite recent financial challenges, the focus on research and development, along with a robust pipeline, suggests a commitment to long-term growth and value creation. The financial metrics indicate a company in the investment phase, with potential for future profitability as products progress through development stages.
AI Generated • Oct 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Timothy John Mitchell, PhD

Website

www.sareum.co.uk

Headquarters

Cambridge, CA CB22 3FX, GB

SAR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-284.01%

Return on Capital

-148.44%

Return on Assets

-152.36%

Earnings Yield

-13.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£38.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

139.73M

Volume

126.37K

Avg. Volume

315.11K

Financials (TTM)

Gross Profit

£0.00

Operating Income

-£7.26M

EBITDA

-£8.75M

Operating Cash Flow

-£5.21M

Capital Expenditure

£1.22M

Free Cash Flow

-£5.21M

Cash & ST Invst.

£2.49M

Total Debt

£0.00

Sareum Plc Performance Analysis

Sareum Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 0N/A
20232023-06-30GBP 0N/A
20242024-06-30GBP 0N/A
20252025-06-30GBP 0N/A
Sareum Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q22024-12-31N/A
Q42025-06-30N/A
Q22025-12-31N/A
Sareum Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP -0.03N/A
20232023-06-30GBP -0.0546.1%
20242024-06-30GBP -0.04-10.0%
20252025-06-30GBP -0.04-14.2%
Sareum Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3068.6%
Q22024-12-31-27.7%
Q42025-06-30-70.6%
Q22025-12-3150.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

£0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

£38.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£7.61M

N/A

Employees

5

N/A

Net Income

-£1.65M

+34.2%

EBITDA

-£1.82M

+27.7%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£2.49M

+509.8%

Total Debt

£0.00

N/A

Accounts Receivable

£747.00K

-50.6%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-1.52%

N/A

Return on Invested Capital

-3.23%

N/A

Free Cash Flow

-£1.52M

+43.2%

Operating Cash Flow

-£1.52M

+43.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
POLB.LPoolbeg Pharma PLC
£0.06-1.54%
RENX.LRenalytix Plc
£0.05+1.87%
IXI.LIXICO plc
£0.08+0.00%
IHC.LInspiration Healthcare Group plc
£0.19+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About SAR

What is the current price of Sareum Plc?

Sareum Plc is trading at £0.27 per share.

What is the 52-week range for Sareum Plc?

Over the past 52 weeks, Sareum Plc has traded between £0.12 and £0.40.

How much debt does Sareum Plc have?

As of the most recent reporting period, Sareum Plc reported total debt of £0.00.

How much cash does Sareum Plc have on hand?

Sareum Plc reported £3.55M in cash and cash equivalents in its most recent financial results.

What is Sareum Plc’s dividend yield?

Sareum Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services